Compare NNNN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | URGN |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2016 |
| Metric | NNNN | URGN |
|---|---|---|
| Price | $16.79 | $33.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 21.2K | ★ 569.0K |
| Earning Date | 04-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | N/A | $129.09 |
| Revenue Next Year | N/A | $70.96 |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.50 | $12.73 |
| 52 Week High | $55.65 | $33.40 |
| Indicator | NNNN | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 71.52 |
| Support Level | $14.66 | $18.58 |
| Resistance Level | $31.12 | N/A |
| Average True Range (ATR) | 3.11 | 1.67 |
| MACD | -0.97 | 0.40 |
| Stochastic Oscillator | 9.95 | 88.77 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.